-transparent.png){kind=logo}
In a multicenter Italian study of 104 adult patients with severe bacterial lower respiratory tract infections, the safety and efficacy of a regimen of high dose, once-daily tobramycin alone or in combination with antipseudomonas betalactams was assessed. The overall bacteriological response was an elimination of the original pathogen in 70% of the patients while the overall clinical response mirrored the bacteriological results with a successful clinical outcome in 78% of patients. Adverse experiences were, in general, few and mild without oto- or nephrotoxicity. The once-daily, high dose regimen of tobramycin proved to be a safe and efficacious therapy for severe lower respiratory tract infections in adult patients.
C Grassi, and
F Ginesu, and
E Pozzi, and
R Rimoldi, and
N Crimi, and
P Periti
January 1991,
Chemotherapy,
C Grassi, and
F Ginesu, and
E Pozzi, and
R Rimoldi, and
N Crimi, and
P Periti
May 1997,
Arzneimittel-Forschung,
C Grassi, and
F Ginesu, and
E Pozzi, and
R Rimoldi, and
N Crimi, and
P Periti
January 1992,
Infection,
C Grassi, and
F Ginesu, and
E Pozzi, and
R Rimoldi, and
N Crimi, and
P Periti
August 1995,
Journal of chemotherapy (Florence, Italy),
C Grassi, and
F Ginesu, and
E Pozzi, and
R Rimoldi, and
N Crimi, and
P Periti
August 1995,
Journal of chemotherapy (Florence, Italy),
C Grassi, and
F Ginesu, and
E Pozzi, and
R Rimoldi, and
N Crimi, and
P Periti
May 2002,
Pediatric pulmonology,
C Grassi, and
F Ginesu, and
E Pozzi, and
R Rimoldi, and
N Crimi, and
P Periti
January 1993,
The Kurume medical journal,
C Grassi, and
F Ginesu, and
E Pozzi, and
R Rimoldi, and
N Crimi, and
P Periti
January 2003,
The Journal of antimicrobial chemotherapy,
C Grassi, and
F Ginesu, and
E Pozzi, and
R Rimoldi, and
N Crimi, and
P Periti
August 1976,
The Journal of infectious diseases,
C Grassi, and
F Ginesu, and
E Pozzi, and
R Rimoldi, and
N Crimi, and
P Periti
December 1991,
The Journal of antimicrobial chemotherapy,
